Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDX1201-A488 is a recombinant, human monoclonal antibody that targets an extracellular epitope of human prostate specific membrane antigen (PSMA). It is conjugated with a fluorescent dye (A488), enabling intra-operative optical imaging. The agent is designed to bind specifically to PSMA-expressing cells, such as those found in prostate cancer, and the attached fluorophore allows surgeons to visualize tumor tissue during procedures like robotic-assisted laparoscopic prostatectomy. This targeted imaging approach aims to improve tumor localization and surgical outcomes by providing real-time visualization of cancerous tissue[2][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MDX1201-A488.